Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tris Pharma, Inc.
A Phase 3, randomized, double-blind, placebo-controlled, parallel group, multicenter, laboratory classroom study. After Screening and Baseline evaluations, eligible subjects are enrolled in the study and entered the open-label phase, dose-optimization phase. TRI102 is taken once daily and subjects undergo dose optimization activities for 5 weeks.
Age
6–12
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Children aged 6 to 12 years with ADHD who require pharmacologic treatment for this condition
You may not be if
Other serious illnesses or conditions that would put the patient at particular risk for safety events or would interfere with treatment/assessment of ADHD